Trikafta treatment can reduce the frequency of pulmonary exacerbations נtimes when lung symptoms get markedly worse נfor people with cystic fibrosis (CF). Thatҳ according to an analysis of real-world data shared at this yearҳ North American Cystic Fibrosis Conference (NACFC), in an oral presentation, Ӊmpact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy use on pulmonary exacerbation [ŝThe post #NACFC2021 ֠Trikafta Reduces Exacerbation Rate, Real-world Data Show appeared first on Cystic Fibrosis News Today